Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Catalent, Inc. (NYSE:CTLT) have received a consensus recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is $63.40.

Separately, StockNews.com initiated coverage on shares of Catalent in a research note on Monday, January 20th. They set a “hold” rating on the stock.

Catalent Stock Performance

CTLT opened at $63.48 on Tuesday. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The business’s 50 day moving average is $62.59 and its 200-day moving average is $60.62. The stock has a market cap of $11.52 billion, a PE ratio of -28.09, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15. Catalent has a twelve month low of $41.15 and a twelve month high of $63.50.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.10) EPS. On average, analysts predict that Catalent will post 0.78 earnings per share for the current year.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.31% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Catalent

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Catalent by 1.5% during the third quarter. State Street Corp now owns 7,451,135 shares of the company’s stock worth $451,315,000 after purchasing an additional 113,095 shares during the period. Millennium Management LLC boosted its stake in shares of Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares during the period. Alpine Associates Management Inc. grew its holdings in shares of Catalent by 3.4% during the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock valued at $129,082,000 after acquiring an additional 69,875 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after acquiring an additional 1,169,044 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Catalent by 5.1% during the second quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock worth $100,818,000 after acquiring an additional 86,533 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.